Results 91 to 100 of about 52,225 (202)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia

Molecular Cancer, 2007
Background Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia.
Groffen John, Pertz Veerle, Müschen Markus, Trageser Daniel, Zhang Bin, Feldhahn Niklas, Kaur Pavinder, Heisterkamp Nora   +7 more
doaj   +1 more source

An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease. [PDF]

Ann Med Surg (Lond), 2021
Al-Janazreh H, Abuzneid YS, Khamayseh I, Morabito F, Alqam B, Abusabbah RMF, Mustafa FK, Sarahneh S.   +7 more
europepmc   +1 more source

Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells. [PDF]

Int J Mol Sci, 2022
Sumi K, Tago K, Nakazawa Y, Takahashi K, Ohe T, Mashino T, Funakoshi-Tago M.   +6 more
europepmc   +1 more source

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

PLoS ONE, 2013
PurposeAberrant PI3K/AKT/mTOR signaling has been linked to oncogenesis and therapy resistance in various malignancies including leukemias. In Philadelphia chromosome (Ph) positive leukemias, activation of PI3K by dysregulated BCR-ABL tyrosine kinase (TK)
Susanne Badura, Tamara Tesanovic, Heike Pfeifer, Sylvia Wystub, Bart A Nijmeijer, Marcus Liebermann, J H Frederik Falkenburg, Martin Ruthardt, Oliver G Ottmann   +8 more
doaj   +1 more source

Impending Cardiac Tamponade as the Initial Manifestation of BCR-ABL Positive Chronic Myeloid Leukemia. [PDF]

Cureus, 2020
Moursy S, Gaballa S, Ahmed A, Hlaing KM, Patel BB.   +4 more
europepmc   +1 more source

Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. [PDF]

Haematologica, 2022
Kayser S, Sartor C, Luskin MR, Webster J, Giglio F, Panitz N, Brunner AM, Fante M, Lutz C, Wolff D, Ho AD, Levis MJ, Schlenk RF, Papayannidis C.   +13 more
europepmc   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.

Cancer Cell, 2008
C. Dierks, R. Beigi, G. Guo, K. Zirlik, M. Stegert, P. Manley, Christopher Trussell, A. Schmitt-Graeff, Klemens Landwerlin, H. Veelken, M. Warmuth   +10 more
semanticscholar   +1 more source

Is There an Entity of Chemically Induced BCR-ABL–Positive Chronic Myelogenous Leukemia?

The Oncologist, 2008
Abstract Learning Objectives After completing this course, the reader will be able to: Distinguish the exogenous causes of acute and chronic myelogenous leukemia.Discuss the evidence establishing the exogenous causes of secondary leukemia.Describe the relationship of radiation and chemical exposure to
openaire   +2 more sources